Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21510767 | 0.94 | SMN1; SMN2 (0.47) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL9094106 | 0.94 | SMN1; SMN2 (0.44) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL9261452 | 0.93 | SMN1; SMN2 (0.49) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL15499882 | 0.93 | SMN1; SMN2 (0.49) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL18811612 | 0.93 | SMN1; SMN2 (0.49) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL21063663 | 0.87 | MAPT (0.40) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL16445934 | 0.86 | CDK5 (0.39) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL19067396 | 0.82 | CDK5 (0.37) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL24963293 | 0.77 | ADORA1 (0.50) | TMIGD3ADORA1HSD17B10ALOX15MAPT | |
| SCHEMBL108390 | 0.77 | MAPT (0.50) | HSD17B10MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112272670-B | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023001061-A1 | CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001061-A1 | CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| CN-112272670-A | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| WO-2020211798-A1 | INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE, AND PREPARATION METHOD AND USES THEREFOR | 上海翰森生物医药科技有限公司 | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211798-A1 | INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE, AND PREPARATION METHOD AND USES THEREFOR | 上海翰森生物医药科技有限公司 | 2020-10-22 | — | — | WO | disclosed |
| US-9687494-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9687494-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2393493-A1 | COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-2250174-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010088394-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088394-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | TMIGD3 1895/4885ADORA1 475/4885HSD17B10 2969/4885 |
| US-20100196321-A1 | COMPOUNDS | HAVCR2, ACE, ACE2 | TMIGD3 4653/4885ADORA1 2051/4885HSD17B10 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.